What is Leerink Partnrs' Forecast for CRBU FY2024 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 earnings estimates for Caribou Biosciences in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.69) for the year, up from their previous estimate of ($1.77). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($0.52) EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

A number of other equities research analysts have also recently issued reports on CRBU. HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $14.00 target price on shares of Caribou Biosciences in a research note on Wednesday, August 7th.

Caribou Biosciences Stock Performance

Caribou Biosciences stock traded up $0.07 during mid-day trading on Monday, reaching $2.75. The company's stock had a trading volume of 1,004,591 shares, compared to its average volume of 1,716,463. The business has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.27. Caribou Biosciences has a twelve month low of $1.50 and a twelve month high of $8.33.

Hedge Funds Weigh In On Caribou Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $2,432,000. Dimensional Fund Advisors LP lifted its holdings in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company's stock valued at $4,302,000 after buying an additional 536,162 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $341,000. Vanguard Group Inc. lifted its holdings in shares of Caribou Biosciences by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company's stock valued at $21,129,000 after buying an additional 148,751 shares during the last quarter. Finally, Milestone Asset Management LLC acquired a new stake in Caribou Biosciences in the 2nd quarter worth approximately $233,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.